Advanced searches left 3/3

Recombinant - Europe PMC

Summarized by Plex Scholar
Last Updated: 13 August 2022

* If you want to update the article please login/register

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.

Following the downswing of protection effectiveness, Waning of neutralizing titres and loss of protection efficiency after the second dose of COVID-19 vaccines was administered, including China-made inactivated vaccines, was observed, including China-made inactivated vaccines. Inactivated vaccine-primed populations, one dose of a recombinant SARS-CoV-2 fusion protein vaccine was tested for restoring the immunity. Within the 3-6 months following the two-dose primary regimen, each eligible participant was given a single dose of Livzon Mabpharm Inc. or placebo, as well as placebo. At 14 days after the increase, a dramatic rise in neutralizing titres was recorded in the V-01 group. According to the intention-to-treat principle, vaccine safety was 47. 8% after two months of surveillance. The heterologous vaccination with the V-01 vaccine was safe and effective, and it could have triggered a heightened degree of humoral immunity in the case of the Omicron variant's epidemic.

Source link: https://europepmc.org/article/MED/35686572


Recombinant adeno-associated virus serotype 9 AAV-RABVG expressing a Rabies Virus G protein confers long-lasting immune responses in mice and non-human primates.

Humans need three or four intramuscular doses of the inactivated human rabies virus vaccines for pre- or post-exposure prophylaxis. In 293T cells infected with AAV9-RABVG, the RABV G protein was stably expressed. AAV9-RABVG delivered robust and long-term positive seroconversions in BALB/c mice with a 100 percent recovery from a lethal RABV challenge. More DCs were activated for effective antigen delivery of RABV G protein in a timely manner, and more B cells were added to be responsible for antibody responses, and antibody responses were triggered in a variety of ways. Significantly more RABV-specific IFN-u3b3-secreting CD4+ and CD8+ T cells, and IL-4-secretive CD4+ T cells were stimulated, and IL-4-secretive CD4+ T cells were stimulated, and elevated levels of IL-2, IFN-u03b3, and IL-10 were also found, resulting in immune responses. Overall, the AAV9-RABVG was a single dose rabies vaccine with a lot of promise by inducing robust, long-term humoral responses, as well as both Th1 and Th2 cell-mediated immune responses in mice and non-human primates.

Source link: https://europepmc.org/article/MED/35579916


Oral vaccination with recombinant Lactobacillus casei expressing Aeromonas hydrophila Aha1 against A. hydrophila infections in common carps.

The expression and localization of the expressed Aha1 protein relative to carrier L. casei were established by western blotting, flow cytometry, and immunofluorescence separately. Besides, a more virulent strain A. hydrophila was discovered in immunized fish, and higher survival rates were observed in immunized fish including Lc-PPG1-Aha1 and Lc-Aha1 after re-infecting with virulent strain A. hydrophila. In addition, the recombinant L. casei was shown a greater propensity for survival in the intestine in immunized fish. The recombinant L. casei strains, when paired together, may be promising candidates for oral vaccination against A. hydrophila infections in common carps.

Source link: https://europepmc.org/article/MED/35499101


A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.

Against esophageal cancer, the present study sought to determine the anti-tumor effectiveness of the epidermal growth factor receptor receptor-targeting fusion protein Fv-LDP-D3 and its antibody-drug conjugate Fv-LDP-D3-AE against esophageal cancer. Through intensive macropinocytosis, cancer cells were introduced to Fv-LDP-D3; it reduced the proliferation and induced apoptosis of esophageal cancer cells. Further, Fv-LDP-D3-AE, a key antibody-drug conjugate produced by integrating the ne chromophore of lidamycin into the Fv-LDP-D3 molecule, showed potent cytotoxicity, stifled migration, and migration, and migration disruption, and DNA loss, arrested cells during G2/M phase, and caused mitochondrial damage in esophageal cancer cells. Both of Fv-LDP-D3-AE and Fv-LDP-D3-AE, as well as Fv-LDP-D3-AE, have markedly reduced the proliferation of esophageal cancer xenografts in athymic mice in athymic mice at moderately tolerated doses. The present findings show that Fv-LDP-D3-D3-AE and Fv-LDP-D3-AE have strong anti-tumor efficacy when targeting EGFR, as well as Fv-LDP-D3-AE, indicating promising candidates for targeted therapy against esophageal cancer.

Source link: https://europepmc.org/article/MED/35416106


Identification of a recombinant equine coronavirus in donkey, China.

Equine coronavirus was first identified in the United States and has since been reported in many countries. We collected 51 small intestinal samples from a donkey foals with diarrhoea from a donkey farm in Shandong Province, China, between August 2020 and April 2021 in order to determine the presence of ECoV in China. The two Chinese strains, according to Bioinformatics' results, are a new genetic variation of ECoV and shared the highest sequence identity of 97. 0 percent with the first detected ECoV strain, NC99.

Source link: https://europepmc.org/article/MED/35311478


Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.

The coronavirus disease pandemic is a major threat to the coronavirus disease pandemic, with vaccine-induced immunity and newly prevalent acute respiratory syndrome coronavirus 2 variants with potential for immune escape. Following two activated COVID-19 vaccinations, two inactivated COVID-19 vaccinations were shown, along with anti-S + N, anti-RBD IgG, and neutralizing antibodies, gradually faded and reduced the neutralizing capacity against emerging Omicron variants. Two boosting initiatives were tested, either with a third dose of inactivated vaccine or a recombinant subunit vaccine based on a recombinant subunit vaccine. The two immunization approaches differed substantially, not only in the number of total NAbs made but also in the composite pattern of NAbs and the number of virus-specific CD4+ T cells produced, according to a later immunological review. Overall, our findings provide valuable evidence for vaccination policies based on available vaccines, which may help with future global vaccination policies.

Source link: https://europepmc.org/article/MED/35230230


Identification of two novel HIV-1 circulating recombinant forms of CRF111_01C and CRF116_0108 in southwestern Yunnan, China.

Yunnan, China's hardest affected by HIV/AIDS, is also a region with the most abundant HIV-1 genetic diversity. Among injection drug users in Yunnan, a large number of novel HIV-1 circulating recombinant forms and unique recombinants had been identified; however, no new recombinant forms or particular recombinants were identified; however, few were found among sexual contacts; only a few were discovered among injection drug users; however, few were discovered among sexual contacts. CRF111_01 C had a CRF01_AE backbone with seven subtype C fragments embedded into the gag, pol, vif, env, nef, and 3'LTR regions, with seven CRF111_01 C fragments embedded into the gag, pol, vif, env, nef, and 3'LTR regions. These two novel HIV-1 CRFs' identifications in this region and the immediate regions highlighted the importance of continuing surveillance in heterosexual contacts and other high-risk groups.

Source link: https://europepmc.org/article/MED/34951549


Immunization with recombinant actin, enolase and 26S proteasome protects Epinephelus coioides against Cryptocaryon irritans

We identified, expressed, and purified three candidate antigens, as well as the P45 protein family from Cryptocaryon irritans, who learned their roles in shielding the grouper from C. irritans infections as subunit vaccines, resulting in their protection of the grouper against C. irritans infections as subunit vaccines. Serum immobilization titer was also performed at 2 and 4 weeks post-immunization. We found that all recombinant CiActin, CiEnolase, and Ci26S proteins provided protection against C. irritans, with the relative survival rates of 36. 7%, 23. 3%, and 46. 7%, respectively. In comparison to the PBS control, the parasite abundance of infected groupers in rCiActin, rCiEnolase, and rCi26S groups has decreased by 71%, 15. 4%, and 67 percent, respectively, in the rCiActin, rCiEnolase, and rCi26S groups decreased by 71%, 15. 4%, and 65%, respectively, down by 70%, 55. 55 percent and compared to the PBS in rCi26S group rCiActin rCiAet's, rCiActin, Conversely, the serum immobilization titers increased in both immunization groups, with rCiActin and rCi26S as the top groups. These results show that the rCiActin and rCi26S can provide a high degree of immunity against C. irritans infection in a grouper and are therefore considered candidate C. irritans vaccines.

Source link: https://europepmc.org/article/MED/IND607803562

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions